Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study
<p>Abstract</p> <p>Aims</p> <p>A number of intervention studies have shown that therapy with angiotensin receptor blockers, such as irbesartan, can improve metabolic parameters and reduce the incidence of diabetes mellitus. It is unknown whether this observation also ho...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-11-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/6/1/36 |
| _version_ | 1818824634975387648 |
|---|---|
| author | Münzel Felix Parhofer Klaus G Krekler Michael |
| author_facet | Münzel Felix Parhofer Klaus G Krekler Michael |
| author_sort | Münzel Felix |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Aims</p> <p>A number of intervention studies have shown that therapy with angiotensin receptor blockers, such as irbesartan, can improve metabolic parameters and reduce the incidence of diabetes mellitus. It is unknown whether this observation also holds true in routine clinical settings.</p> <p>Methods</p> <p>We evaluated the effect of irbesartan (150 mg or 300 mg/d) together with or without hydrochlorothiazide (12.5 mg/d) in 3259 German patients. A total of 750 primary care physicians evaluated up to 5 subsequent patients with metabolic syndrome (58.9% diabetic), in whom irbesartan therapy was newly initiated (87%) or continued (13%).</p> <p>Results</p> <p>Six months of irbesartan therapy decreased systolic blood pressure by 14% (157.4 ± 14.7 vs. 135.0 ± 10.7 mmHg) and diastolic blood pressure by 13% (92.9 ± 9.2 vs. 80.8 ± 6.8 mmHg). This was associated with a decrease in body weight (-2.3%), fasting glucose (-9.5%), HbA1c (-4.6%), LDL-cholesterol (-11%), triglycerides (-16%) and gamma-GT (-12%) and an increase in HDL-cholesterol (+5%). These changes were somewhat more pronounced in male than in female patients and in obese than in lean patients. Changes in glucose concentration and HbA1c were much more prominent in diabetic patients.</p> <p>Conclusion</p> <p>Irbesartan therapy improves metabolic parameters in routine clinical settings. Thus, our study confirms previously published results from large intervention trials and extends the findings to routine clinical practice.</p> |
| first_indexed | 2024-12-18T23:59:00Z |
| format | Article |
| id | doaj.art-8068e5fedb2e4df7a01ef332c2ec8cbd |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-18T23:59:00Z |
| publishDate | 2007-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-8068e5fedb2e4df7a01ef332c2ec8cbd2022-12-21T20:46:35ZengBMCCardiovascular Diabetology1475-28402007-11-01613610.1186/1475-2840-6-36Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational studyMünzel FelixParhofer Klaus GKrekler Michael<p>Abstract</p> <p>Aims</p> <p>A number of intervention studies have shown that therapy with angiotensin receptor blockers, such as irbesartan, can improve metabolic parameters and reduce the incidence of diabetes mellitus. It is unknown whether this observation also holds true in routine clinical settings.</p> <p>Methods</p> <p>We evaluated the effect of irbesartan (150 mg or 300 mg/d) together with or without hydrochlorothiazide (12.5 mg/d) in 3259 German patients. A total of 750 primary care physicians evaluated up to 5 subsequent patients with metabolic syndrome (58.9% diabetic), in whom irbesartan therapy was newly initiated (87%) or continued (13%).</p> <p>Results</p> <p>Six months of irbesartan therapy decreased systolic blood pressure by 14% (157.4 ± 14.7 vs. 135.0 ± 10.7 mmHg) and diastolic blood pressure by 13% (92.9 ± 9.2 vs. 80.8 ± 6.8 mmHg). This was associated with a decrease in body weight (-2.3%), fasting glucose (-9.5%), HbA1c (-4.6%), LDL-cholesterol (-11%), triglycerides (-16%) and gamma-GT (-12%) and an increase in HDL-cholesterol (+5%). These changes were somewhat more pronounced in male than in female patients and in obese than in lean patients. Changes in glucose concentration and HbA1c were much more prominent in diabetic patients.</p> <p>Conclusion</p> <p>Irbesartan therapy improves metabolic parameters in routine clinical settings. Thus, our study confirms previously published results from large intervention trials and extends the findings to routine clinical practice.</p>http://www.cardiab.com/content/6/1/36 |
| spellingShingle | Münzel Felix Parhofer Klaus G Krekler Michael Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study Cardiovascular Diabetology |
| title | Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study |
| title_full | Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study |
| title_fullStr | Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study |
| title_full_unstemmed | Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study |
| title_short | Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study |
| title_sort | effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice the do it prospective observational study |
| url | http://www.cardiab.com/content/6/1/36 |
| work_keys_str_mv | AT munzelfelix effectoftheangiotensinreceptorblockerirbesartanonmetabolicparametersinclinicalpracticethedoitprospectiveobservationalstudy AT parhoferklausg effectoftheangiotensinreceptorblockerirbesartanonmetabolicparametersinclinicalpracticethedoitprospectiveobservationalstudy AT kreklermichael effectoftheangiotensinreceptorblockerirbesartanonmetabolicparametersinclinicalpracticethedoitprospectiveobservationalstudy |